3Goel A, Boland CR, Chauhan DP. Specific inhibition of eyclooxygenase-2 (COX-2) expression by dietary curcu- rain in HT-29 human colon cancer cells[J]. Cancer Lett, 2001,172(2) .. 111-118.
4Surh YJ,Chun KS, Cha HH, et al. Molecular mecha- nisms underlying chemopreventive activities of anti-in- flammatory phytochemicaIs: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation [J]. Murat Res,2001,480-481(11) :243-268.
5Chan MM, Huang HI,Fenton MR, et al. In vivo inhibition of nitric oxide synthase gene expression by eureumin, acancer preventive natural product with anti-inflammatory properties[J]. Biochem Pharmacoh 1998,55 ( 12 ) : 1955- 1962.
6Sarkar FH, Li Y. Cell signaling pathways altered by natu- ral chemopreventive agents[J]. Mutat Res, 2004,555 ( 1- 2) :53-64.
7Aggarwal BB. Signalling pathways of the TNF superfami- ly:a double-edged sword[J]. Nat Rev Immunol, 2003,3 (9) :745-756.
8Shishodia S, Amin HM, Lai R, et al. Curcumin (diferu- loylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and in- duces apoptosis in mantle cell lymphoma [J]. Biochem Pharmacol, 2005,70 (5) : 700-713.
2Wang YJ, Pan MH, Cheng AL et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharmaceu & Biomed Analysis, 1997 ; 15 (12) : 1867-76.
3Oetari S, Sudibyo M, Commandeur Jan NM et al, Effects of curcumin on cytochrome p450 and glutathione S-transferase activities in rat liver. Biochem Pharmacol, 1996,51(1) : 39-45.
4Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol, 1978;43(2) :86-92.
5Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin ( 1,7-his-( 4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica, 1978;8(12):761-8.
6Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Tozicology, 1980;16 (3): 25965.
7Ravindranath V, Chandrasekhara N. Metabolism of curcuminstudies with [^3 H]curcumin. Toxicology, 1982; 22 : 337 - 44.
8Ravindranath V, Chandrasekhara N. In Vitro studies on the intestinal absorption of curcumin in rats. Toxicology, 1981;20(2-3): 251-7.
9Shoba G, Joy D, Joseph T et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers.Planta Medica , 1998;64:353-6.
10Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metabolitism & Disposition, 1999;27(4) :486-94.
3Taubman M A,Valverde P,Han X,et al.Immune response:the key to bone resorption in periodontal disease[J].J Periodontol,2005,76(11 Suppl):2033-2041.
4Zhao F,Gong Y,Hu Y,et al.Curcumin and its major metabolites inhibit the inflammatory response induced by lipopolysaccharide:Translocation of nuclear factor-κB as potential target[J].Molecular Medicine Reports,2015,11(4):3087-3093.
5Biswas S,Rahman I.Modulation of steroid activity in chronic inflammation:a novel anti-inflammatory role for curcumin[J].Mol Nutr Food Res,2008,52(9):987-994.
6Hanai H,Sugimoto K.Curcumin has bright prospects for the treatment of inflammatory bowel disease[J].Curr Pharm Design,2009,15(18):2087-2094.
7Bainbridge B W,Darveau R P.Porphyromonas gingivalis lipopolysaccharide:an unusual pattern recognition receptor ligand for the innate host defense system[J].Acta Odontol Scand,2001,59(3):131-138.
8Bergamini A,Bolacchi F,Bongioyanni B,et al.Granulocyte–macrophage colony-stimulating factor regulates cytokine production in cultured macrophages through CD14-dependent and-independent mechanisms[J].Immunology,2000,101(2):254-262.
9Waraaswapati N,Chayasadom A,Surarit R,et al.Induction of Toll-like receptor expression by Porphyromonas gingivalis[J].J Periodontol,2013,84(7):1010-1018.
10Ertugrul A S,Sahin H,Dikilitas A,et al.Comparison of CCL28,in-terleukin-8,interleukin-1βand tumor necrosis factor-alpha in subjects with gingivitis,chronic periodontitis and generalized ag-gressive periodontitis[J].J Periodontal Res,2013,48(1):44-51.
